Limited Distribution Network for DOPTELET® Includes Biologics by McKesson

Dova Pharmaceuticals (Dova) is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia.

Dova’s proprietary pipeline includes one commercial product, DOPTELET^®, for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure and the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment (ITP). 

A supplemental New Drug Application (sNDA) was approved in June 2019 that expanded the use of DOPTELET to include the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Dova recently entered into a merger agreement with Swedish Orphan Biovitrum AB (Sobi). The proposed transaction is anticipated to enhance Sobi’s position as a leader in hematology and orphan diseases and expand its presence in the United States.

Additionally, Sobi intends to leverage its strong international presence to maximize the availability and commercial potential of DOPTELET globally. There are approximately 60,000 U.S. patients with ITP representing a market opportunity of $1 billion. (1)

Biologics by McKesson was recently selected by a subsidiary of Dova as a specialty pharmacy provider in a limited distribution network for DOPTELET. Dova selected Biologics to help provide high-touch clinical support to patients.

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive.

Takeaway: Dova Pharmaceuticals projects the ITP market to grow 15% annually.

(1) Dova Pharmaceuticals Corporate Overview, September 24, 2019